Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020068391 - METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT

Publication Number WO/2020/068391
Publication Date 02.04.2020
International Application No. PCT/US2019/049791
International Filing Date 05.09.2019
IPC
A61K 31/4164 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/43 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/7036 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
7036having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 38/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14Peptides containing saccharide radicals; Derivatives thereof
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/55594
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55588Adjuvants of undefined constitution
55594from bacteria
A61K 2039/572
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
572cytotoxic response
A61K 2039/585
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
58raising an immune response against a target which is not the antigen used for immunisation
585wherein the target is cancer
A61K 31/4164
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/43
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
Applicants
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US]/[US]
  • THE BROAD INSTITUTE, INC. [US]/[US]
Inventors
  • JIN, Chengcheng
  • LAGOUDAS, Georgia
  • JACKS, Tyler
  • BLAINEY, Paul
Agents
  • RAYMOND, Adam S.
  • HODGES, Robert A.
  • SHYNTUM, Yvonne Y.
  • YONGYE, Austin B.
  • MONHEIT, Rivka D.
  • PABST, Patrea L.
  • SARGSYAN, S. Anna
  • ZUNIGA, Carlos A.
  • CALDERON MOLINA, Angie D.
  • XU, Xiaojin
Priority Data
16/449,10021.06.2019US
62/727,95506.09.2018US
62/769,21519.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT
(FR) MÉTHODES ET COMPOSITIONS CIBLANT LE MICROBIOTE PULMONAIRE ET SES VOIES IMMUNITAIRES RÉPONDANTES POUR LE TRAITEMENT DU CANCER DU POUMON
Abstract
(EN)
It has been discovered that lung tumor growth is associated with a dysregulation of the local microbiota, including an increased total bacterial load and reduced bacterial diversity in the airway. In the lungs, commensal bacteria, which are otherwise non-pathogenic and colonize pulmonary tissue at a much lower density in healthy individuals, provoke chronic inflammation and exacerbation of lung cancer through tumor-infiltrating immune cells. Thus, targeting the lung microbiota and its responding immune pathways is useful in treating lung cancer. Disclosed are compositions and methods targeting the lung microbiota and its responding immune pathways in a subject by specific targeting of commensal bacteria in the subject. Typically, the methods involve administering an effective amount of one or more therapeutics such as an antibiotic that reduces the local bacterial load, blocks or depletes tumor-infiltrating immune cells, and/or locally inhibits one or more cytokines or chemokines.
(FR)
La présente invention concerne la découverte que la croissance d'une tumeur pulmonaire est associée à une dysrégulation du microbiote local, y compris une charge bactérienne totale accrue et une diversité bactérienne réduite dans les voies respiratoires. Dans les poumons, les bactéries commensales, qui sont par ailleurs non pathogènes et colonisent le tissu pulmonaire à une densité beaucoup plus faible chez les individus sains, provoquent une inflammation chronique et une exacerbation du cancer du poumon par l'intermédiaire de cellules immunitaires infiltrant les tumeurs. Ainsi, le ciblage du microbiote pulmonaire et de ses voies immunitaires répondantes est utile dans le traitement du cancer du poumon. L'invention concerne des compositions et des méthodes ciblant le microbiote pulmonaire et ses voies immunitaires répondantes chez un sujet par ciblage spécifique de bactéries commensales chez le sujet. Typiquement, les méthodes impliquent l'administration d'une quantité efficace d'un ou de plusieurs agents thérapeutiques tels qu'un antibiotique qui réduit la charge bactérienne locale, bloque ou épuise les cellules immunitaires infiltrant les tumeurs, et/ou inhibe localement une ou plusieurs cytokines ou chimiokines.
Also published as
Latest bibliographic data on file with the International Bureau